Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: Correlation with clinical and immunological parameters and with the response to auranofin treatment

L. Boiardi, P. Macchioni, C. Salvarani, F. Rossi, F. R M Casadei-Maldini, R. Mancini, E. Beltrandi, I. Portioli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. 38 untreated patients suffering from rheumatoid arthritis (RA) were studied to evaluate the relationship between serum sIL-2R levels and laboratory and clinical indexes of disease activity and circulating lymphocyte subpopulations. Furthermore, we serially analyzed the correlation between the clinical response to oral gold (Auranofin) treatment and serum sIL-2R levels in 28 RA patients. Methods. Patients received a complete rheumatological examination at entry and every 3 months during the study. A complete biochemical analysis was executed every month. Serum sIL-2R levels were evaluated before entering and at the 3rd and 6th month by ELISA. Phenotype analysis of peripheral blood mononuclear cells was performed by a two-color technique using the association of specific monoclonal antibodies. Samples were analyzed by a FACS-scan 440 cytofluorimeter with a single Argonion laser. Results. Serum sIL-2R were significantly higher in RA patients than in controls and had a significant negative correlation with disease duration and a positive correlation with serum IgG and C3 levels. A significant positive correlation was found between serum sIL-2R levels and circulating CD3+HLADR+, CD3-HLADR+ and CD20+CD5- cells. After 6 months of auranofin therapy no differences in serum sIL-2R in comparison with basal levels were found in either responders or in non-responders. Conclusion. Serum sIL-2R level is not a good index of activity in RA patients and is not a useful marker of response to AU therapy.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalClinical and Experimental Rheumatology
Volume12
Issue number4
Publication statusPublished - 1994

Fingerprint

Auranofin
Interleukin-2 Receptors
Rheumatoid Arthritis
Serum
Therapeutics
Lymphocyte Subsets
Gold
Blood Cells
Lasers
Color
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies
Phenotype

Keywords

  • auranofin
  • rheumatoid arthritis
  • serum sIL-2R

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Serum soluble interleukin-2 receptor levels in rheumatoid arthritis : Correlation with clinical and immunological parameters and with the response to auranofin treatment. / Boiardi, L.; Macchioni, P.; Salvarani, C.; Rossi, F.; Casadei-Maldini, F. R M; Mancini, R.; Beltrandi, E.; Portioli, I.

In: Clinical and Experimental Rheumatology, Vol. 12, No. 4, 1994, p. 357-362.

Research output: Contribution to journalArticle

Boiardi, L. ; Macchioni, P. ; Salvarani, C. ; Rossi, F. ; Casadei-Maldini, F. R M ; Mancini, R. ; Beltrandi, E. ; Portioli, I. / Serum soluble interleukin-2 receptor levels in rheumatoid arthritis : Correlation with clinical and immunological parameters and with the response to auranofin treatment. In: Clinical and Experimental Rheumatology. 1994 ; Vol. 12, No. 4. pp. 357-362.
@article{a55db93b32b04d75b3337734d78576d5,
title = "Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: Correlation with clinical and immunological parameters and with the response to auranofin treatment",
abstract = "Objective. 38 untreated patients suffering from rheumatoid arthritis (RA) were studied to evaluate the relationship between serum sIL-2R levels and laboratory and clinical indexes of disease activity and circulating lymphocyte subpopulations. Furthermore, we serially analyzed the correlation between the clinical response to oral gold (Auranofin) treatment and serum sIL-2R levels in 28 RA patients. Methods. Patients received a complete rheumatological examination at entry and every 3 months during the study. A complete biochemical analysis was executed every month. Serum sIL-2R levels were evaluated before entering and at the 3rd and 6th month by ELISA. Phenotype analysis of peripheral blood mononuclear cells was performed by a two-color technique using the association of specific monoclonal antibodies. Samples were analyzed by a FACS-scan 440 cytofluorimeter with a single Argonion laser. Results. Serum sIL-2R were significantly higher in RA patients than in controls and had a significant negative correlation with disease duration and a positive correlation with serum IgG and C3 levels. A significant positive correlation was found between serum sIL-2R levels and circulating CD3+HLADR+, CD3-HLADR+ and CD20+CD5- cells. After 6 months of auranofin therapy no differences in serum sIL-2R in comparison with basal levels were found in either responders or in non-responders. Conclusion. Serum sIL-2R level is not a good index of activity in RA patients and is not a useful marker of response to AU therapy.",
keywords = "auranofin, rheumatoid arthritis, serum sIL-2R",
author = "L. Boiardi and P. Macchioni and C. Salvarani and F. Rossi and Casadei-Maldini, {F. R M} and R. Mancini and E. Beltrandi and I. Portioli",
year = "1994",
language = "English",
volume = "12",
pages = "357--362",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Serum soluble interleukin-2 receptor levels in rheumatoid arthritis

T2 - Correlation with clinical and immunological parameters and with the response to auranofin treatment

AU - Boiardi, L.

AU - Macchioni, P.

AU - Salvarani, C.

AU - Rossi, F.

AU - Casadei-Maldini, F. R M

AU - Mancini, R.

AU - Beltrandi, E.

AU - Portioli, I.

PY - 1994

Y1 - 1994

N2 - Objective. 38 untreated patients suffering from rheumatoid arthritis (RA) were studied to evaluate the relationship between serum sIL-2R levels and laboratory and clinical indexes of disease activity and circulating lymphocyte subpopulations. Furthermore, we serially analyzed the correlation between the clinical response to oral gold (Auranofin) treatment and serum sIL-2R levels in 28 RA patients. Methods. Patients received a complete rheumatological examination at entry and every 3 months during the study. A complete biochemical analysis was executed every month. Serum sIL-2R levels were evaluated before entering and at the 3rd and 6th month by ELISA. Phenotype analysis of peripheral blood mononuclear cells was performed by a two-color technique using the association of specific monoclonal antibodies. Samples were analyzed by a FACS-scan 440 cytofluorimeter with a single Argonion laser. Results. Serum sIL-2R were significantly higher in RA patients than in controls and had a significant negative correlation with disease duration and a positive correlation with serum IgG and C3 levels. A significant positive correlation was found between serum sIL-2R levels and circulating CD3+HLADR+, CD3-HLADR+ and CD20+CD5- cells. After 6 months of auranofin therapy no differences in serum sIL-2R in comparison with basal levels were found in either responders or in non-responders. Conclusion. Serum sIL-2R level is not a good index of activity in RA patients and is not a useful marker of response to AU therapy.

AB - Objective. 38 untreated patients suffering from rheumatoid arthritis (RA) were studied to evaluate the relationship between serum sIL-2R levels and laboratory and clinical indexes of disease activity and circulating lymphocyte subpopulations. Furthermore, we serially analyzed the correlation between the clinical response to oral gold (Auranofin) treatment and serum sIL-2R levels in 28 RA patients. Methods. Patients received a complete rheumatological examination at entry and every 3 months during the study. A complete biochemical analysis was executed every month. Serum sIL-2R levels were evaluated before entering and at the 3rd and 6th month by ELISA. Phenotype analysis of peripheral blood mononuclear cells was performed by a two-color technique using the association of specific monoclonal antibodies. Samples were analyzed by a FACS-scan 440 cytofluorimeter with a single Argonion laser. Results. Serum sIL-2R were significantly higher in RA patients than in controls and had a significant negative correlation with disease duration and a positive correlation with serum IgG and C3 levels. A significant positive correlation was found between serum sIL-2R levels and circulating CD3+HLADR+, CD3-HLADR+ and CD20+CD5- cells. After 6 months of auranofin therapy no differences in serum sIL-2R in comparison with basal levels were found in either responders or in non-responders. Conclusion. Serum sIL-2R level is not a good index of activity in RA patients and is not a useful marker of response to AU therapy.

KW - auranofin

KW - rheumatoid arthritis

KW - serum sIL-2R

UR - http://www.scopus.com/inward/record.url?scp=0028038345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028038345&partnerID=8YFLogxK

M3 - Article

C2 - 7955597

AN - SCOPUS:0028038345

VL - 12

SP - 357

EP - 362

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -